Recombine

The firm's core business was providing carrier screening services to prospective parents. These services were designed to identify genetic carrier statuses, enabling clients, primarily IVF clinics and OB-GYN specialists, to make informed decisions about family planning. By identifying risks before or during early pregnancy, Recombine empowered couples to understand the chances of passing on hereditary conditions to their children. The company managed the entire process, from sample collection and laboratory analysis to results interpretation and genetic counseling.

Recombine's flagship product was the CarrierMap, an expanded carrier screening panel that tested for over 250 genetic diseases from a single blood or saliva sample. This comprehensive test was applicable to individuals of all ethnicities, offering broad disease coverage and detection. The company also developed ChromoMap, a non-invasive prenatal test to analyze fetal chromosome health. A significant milestone was reached in May 2016 when CooperSurgical, a unit of The Cooper Companies, acquired the commercial assets of Recombine for approximately $85 million. At the time of the sale, Recombine had achieved trailing twelve-month revenues of around $20 million.